home / peer-exchange / therapy-options-in-hr-positive-her2-negative-breast-cancer
Expert oncologists Hope S. Rugo, MD, FASCO; Aditya Bardia, MD, MPH; Komal Jhaveri, MD, FACP; Mark Pegram, MD; and Anne O'Dea, MD, review data from recent conferences and discuss updates in the management of HR+/HER2- breast cancer.